Retatrutide has moved beyond early-stage clinical research into a broad Phase 3 development program. Results reported in 2026 have increased scientific interest because multiple trials have reported substantial changes in body weight and other metabolic measures. But Phase 3 results still need to be interpreted carefully. Some 2026 findings have been released as topline company results and are awaiting detailed peer-reviewed publication. Retatrutide also remains investigation